Cargando…

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer

Epithelial ovarian cancer remains the deadliest gynecologic malignancy. Despite advances in treatment, new approaches are needed. Histone deacetylases (HDACs) are a family of enzymes that regulate gene expression by removing acetyl groups from lysine residues on histones and non-histone proteins. In...

Descripción completa

Detalles Bibliográficos
Autor principal:	Khabele, Dineo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033132/ https://www.ncbi.nlm.nih.gov/pubmed/24904826 http://dx.doi.org/10.3389/fonc.2014.00111

Ejemplares similares

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
por: Guo, Fengyi, et al.
Publicado: (2022)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
por: Wilson, Andrew J, et al.
Publicado: (2012)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
por: Wang, Guan, et al.
Publicado: (2012)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
por: Shojaei, Farbod, et al.
Publicado: (2022)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
por: McCaw, Tyler R., et al.
Publicado: (2020)

Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

Characterization of Histone Deacetylase Mechanisms in Cancer Development
por: Hai, Rihan, et al.
Publicado: (2021)

Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma
por: Torres, Haydee M., et al.
Publicado: (2021)

Evaluation of Histone Deacetylase Inhibitors as Radiosensitizers for Proton and Light Ion Radiotherapy
por: Johnson, Alicia M., et al.
Publicado: (2021)

Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
por: Pramanik, Siddhartha Das, et al.
Publicado: (2022)

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
por: Chen, Chi-Yuan, et al.
Publicado: (2020)

Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues
por: GU, YIFENG, et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
por: Gupta, Vijayalaxmi, et al.
Publicado: (2018)

Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis
por: Wang, Changjun, et al.
Publicado: (2022)

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension
por: Chelladurai, Prakash, et al.
Publicado: (2020)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
por: Jewell, Andrea, et al.
Publicado: (2018)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications
por: Chaiyawat, Parunya, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
por: Perla, Alexandre, et al.
Publicado: (2020)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Eloquent silence: developmental functions of Class I histone deacetylases
por: Cunliffe, Vincent T
Publicado: (2008)

Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
por: Yang, Qiwei, et al.
Publicado: (2022)

Medicinal chemistry advances in targeting class I histone deacetylases
por: Abdallah, Diaaeldin I., et al.
Publicado: (2023)

Class I histone deacetylase complex: Structure and functional correlates
por: Wang, Xiao, et al.
Publicado: (2023)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
por: Traoré, Mohamed D. M., et al.
Publicado: (2017)

Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents
por: Tapadar, Subhasish, et al.
Publicado: (2020)

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

Next-generation of selective histone deacetylase inhibitors
por: Yang, Feifei, et al.
Publicado: (2019)

Potential use of histone deacetylase inhibitors in cancer therapy
por: Gołąbek, Karolina, et al.
Publicado: (2015)

Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor
por: Chutake, Yogesh K., et al.
Publicado: (2016)

Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
por: Marsh, Deborah J., et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
por: Wells, Christina E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8rs4nth56jpu6n3rsdnh31e2ai